# Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Source: https://onco.cc/trials/nct06393374/  
OnCo record `nct06393374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan and Capecitabine in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1530 participants. Primary completion is estimated at 2030-12-16. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine. Registered primary measures: Invasive Disease-Free Survival (iDFS).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06393374
- Phase: 3
- Setting: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 1530

## Notes

- ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1530 participants. Primary completion is estimated at 2030-12-16. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06393374: https://clinicaltrials.gov/study/NCT06393374

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06393374.json